GlassScriptPhysician profile
Jed P Naisbitt
NPI 1487677613
$562.56
in general payments reported to CMS, 2019-2025
14 companies · $37.27 in 2025
The $37.27 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $81.39 · 2021: $75.60 · 2022: $58.50 · 2023: $29.68 · 2024: $94.47 · 2025: $37.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $129 · Long Term Medical Supply Or Device Loan: $32.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $129.34 |
| Long Term Medical Supply Or Device Loan | $32.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $114.11 | 2019-2025 | Novasure |
| Allergan, INC. | $86.11 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.57 | 2019-2020 | |
| Medtronic Vascular, INC. | $44.70 | 2019 | |
| Abbvie INC. | $44.19 | 2022-2023 | |
| Astellas Pharma US INC | $35.40 | 2024-2025 | Veozah |
| Therapeuticsmd, INC. | $34.72 | 2019-2020 | |
| Baxter Healthcare | $32.08 | 2024 | Hillrom - Spot Vision Screener |
| Galderma Laboratories, L.P. | $26.13 | 2021 | |
| Becton, Dickinson and Company | $16.40 | 2024 | Bd Onclarity |
| Duchesnay USA Incorporated | $16.05 | 2019 | |
| Exeltis, USA INC. | $14.77 | 2024 | Slynd |
| Organon LLC | $14.69 | 2024 | |
| Medtronic, INC. | $11.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jed Naisbitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.